|
[1] Newman D J, Cragg G M, Snader K M, et al. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod, 2003, 66: 1022-1037.
[2] Thibodeaux C J, Melancon C E, Liu H W, et al. Unusual sugar biosynthesis and natural product glycodiversification. Nature, 2007, 446: 1008-1016.
[3] Sosio M, Stinchi S, Beltrametti F, et al. The gene cluster for the biosynthesis of the glycopeptide antibiotic A40926 by nonomuraea species. Chem Biol, 2003,10(6): 541-549.
[4] Langenhan J M, Griffith B R, Thorson J S, et al. Neoglycorandomization and chemoenzymatic glycorandomization: Two complementary tools fornatural product diversification. J Nat Prod, 2005, 68: 1696-1711.
[5] Thibodeaux C J, Liu H W. Manipulating nature’s sugar biosynthetic machineries for glycodiversification of macrolides: Recent advances and future prospects. Pure Appl Chem, 2007, 79(4): 785-799.
[6] Leadlay P F. Combinatorial approaches to polyketide biosynthesis. Current Opinion in Chemical Biology, 1997, 1: 162-166.
[7] Floss H G. Antibiotic biosynthesis: from natural to unnatural compounds. Journal of Industrial Microbiology & Biotechnology, 2001, 27: 183-194.
[8] Méndez C, Salas J A. Altering the glycosylation pattern of bioactive compounds. Trends in Biotechnology, 2001, 19(11): 449-456.
[9] Fu X, Albermann C, Jiang J, et al. Antibiotic optimization via in vitro glycorandomization. Nature Biotechnology. 2003, 21: 1467-1469.
[10] Yang J, Hoffmeister D, Liu L, et al. Natural product glycorandomization. Bioorganic & Medicinal Chemistry, 2004, 12: 1577-1584.
[11] Rupprath C, Schumacher T, Elling L, et al. Nucleotide deoxysugars: essential tools for the glycosylation engineering of novel bioactive compounds. Curr Med Chem, 2005, 12(14):1637-1675.
[12] Melann C E, Thibodeaux C J, Liu H W, et al. Glyco-stripping and glyco-swapping. ACS Chemical Biology, 2006, 1(8): 499-504.
[13] Salas J A, Mendez C. Engineering the glycosylation of natural products in actinomycetes. Trends in Microbiology, 2007, 15(5): 219-232.
[14] Alexander C. Weymouth-Wilson. The role of carbohydrates in biologically active natural products. Nat Prod Rep, 1997, 14: 99-110.
[15] Hu Y, Walker S. Remarkable structural similarities between diverse glycosyltransferases. Chem Biol, 2002, 9(12):1287-1296.
[16] Mulichak A M, Losey H C, Garavito R M, et al. Structure of the UDP-glucosyltransferase GtfB that modifies the heptapeptide aglycone in the biosynthesis of vancomycin grou Pantibiotics. Structure, 2001, 9: 547-557.
[17] Mulichak A M, Losey H C, Garavito R M, et al. Structure of the TDP-epi-vancosaminyltransferase GtfA from the chloroeremomycin biosynthetic pathway. PNAS, 2003, 100(16): 9238-9243.
[18] Mulichak A M, Losey H C, Garavito R M, et al. Crystal structure of vancosaminyltransferase GtfD from the vancomycin biosynthetic pathway: Interactions with acceptor and nucleotide ligands. Biochemistry, 2004, 43: 5170-5180.
[19] Hu Y, Chen L, Walker S, et al. Crystal structure of the MurG:UDP-GlcNAc complex reveals common structural principles of a superfamily of glycosyltransferases. PNAS, 2003, 100(3): 845-849.
[20] Sinnott M L. Catalytic mechanisms of enzymic glycosyl transfer. Chem Rev,1990, 90: 1171-1202.
[21] Koshland D E. Stereochemistry and the mechanism of enzymatic reactions. Biol Rev Camb Phil Soc, 1953,28(4): 416-436.
[22] Withers S G, Lairson L L, Henrissat B, et al. Glycosyltransferases: structures, functions, and mechanisms. Annu Rev Biochem, 2008,77:521-555.
[23] Salas J A, Sanchez C, Zhu L, et al. Combinatorial biosynthesis of antitumor indolocarbazole compounds. PNAS, 2005, 102(2): 461-466.
[24] Hong Jay Sung Joong, Park S H, Yoon Y J, et al. New olivosyl derivatives of methymycin/pikromycin from an engineered strain of Streptomyces venezuelae. FEMS Microbiology Letters, 2004, 238: 391-399.
[25] Blanchard S, Thorson J S. Enzymatic tools for engineering natural product glycosylation. Current Opinion in Chemical Biology 2006, 10: 263-271.
[26] Hoffmeiste Ichinose K, Bechthold A. Two sequence elements of glycosyltransferases involved in urdamycin biosynthesis are responsible for substrate specificity and enzymatic activity. Chemistry & Biology, 2007, 8(6): 557-567.
[27] Hoffmeister D, Wilkinson B, Ichinose K, et al. Engineered urdamycin glycosyltransferases are broadened and altered in substrate specificity. Chem & Biology, 2002, 9: 287-295.
[28] Thorson J S, Williams G J, Zhang C, et al. Expanding the promiscuity of a natural-product glycosyltransferase by directed evolution. Nat Chem Biol, 2007, 3(10): 657-662.
[29] Kim B G, Park S H, Park H Y, et al. Reconstitution of antibiotics glycosylation by domain exchanged chimeric Glycosyltransferase. Journal of Molecular Catalysis B: Enzymatic, 2009, 60: 29-35.
[30] Thorson J S, Griffith B R, Langenhan J M, et al. ‘Sweetening’ natural products via glycorandomization. Current Opinion in Biotechnology, 2005, 16: 622-630.
[31] Chisholm J D, Van Vranken D L. Regiocontrolled Synthesis of the Antitumor Antibiotic AT2433-A1. J Org Chem, 2000, 65: 7541-7553.
[32] Thorson J S, Langenhan J M, Peters N R, et al. Enhancing the anti-cancer properties of cardiac glycosides via neoglycorandomization. Proc Natl Acad Sci, 2005, 102(35): 12305-12310.
[33] Educhi T, Minami A, Kakinuma K, et al. Aglycon switch approach toward unnatural glycosides from natural glycoside with glycosyltransferase VinC. Tetrahedron Lett, 2005, 46(37): 6187-6190.
[34] Zhang C, Griffith B R, Thorson J S, et al. Exploiting the reversibility of natural product glycosyltransferase-catalyzed reactions. Science, 2006, 313: 1290-1294.
|
